Zobrazeno 1 - 10
of 25
pro vyhledávání: '"S de Ducla"'
Autor:
José Bines, Joseph Gligorov, Emilio Alba, Giorgio Mustacchi, S de Ducla, P Button, Dinesh Chandra Doval, Paulo Cortes
Publikováno v:
Cancer Research. 77:P5-15
BACKGROUND The open-label randomized phase III IMELDA trial demonstrated that adding CAP to maintenance BEV until disease progression after initial BEV + docetaxel (DOC) provides statistically significant and clinically meaningful improvements in bot
Autor:
Robert Huddart, Cora N. Sternberg, Yohann Loriot, Michal Mego, B. Mellado Gonzalez, Andre P. Fay, D. Castellano Gauna, S. de Ducla, Michael Ong, Craig Gedye, Howard Gurney, Aristotle Bamias, Simon Fear, Julie Pavlova, Axel S. Merseburger, Jens Voortman
Publikováno v:
Annals of Oncology. 31:S591
Autor:
Claudia Caserta, Daniel P. Petrylak, Laura Galli, Roberto Sabbatini, Roberto Iacovelli, S. de Ducla, Jonathan E. Rosenberg, J.L. Perez Gracia, Emanuele Naglieri, Beiying Ding, Margitta Retz, Teresa Bonfill, Marco Maruzzo, R. Morales Barrera, J. Linsenmeier, Jean H. Hoffman-Censits, Robert Dreicer, Raymond S. McDermott, Cora N. Sternberg, M.S. van der Heijden
Publikováno v:
Annals of Oncology. 30:v372-v373
Autor:
Lada Mitchell, M. Martin, Mikhail Lichinitser, S de Ducla, A. Makhson, A. Lluch, Joseph Gligorov, Vladimir Semiglazov, Sergei Tjulandin
Publikováno v:
Cancer Research. 73:P4-12
Background: After median follow-up of 8.8 months, the primary efficacy results from the HAX study [Martín et al., Oncologist 2012] demonstrated a 73% overall response rate (ORR) according to RECIST (primary endpoint), median progression-free surviva
Autor:
S. Li, Annie Guerin, Sherry Shi, Shuqian Liu, John T. Leppert, S.-W. Lin, N. Vander Velde, Lizheng Shi, S. de Ducla, Raluca Ionescu-Ittu, Christina Louise Derleth, Jingjing Wang, Eric Q. Wu
Publikováno v:
Value in Health. 20:A421
Publikováno v:
Annals of Oncology. 27:vi73
Autor:
S. de Ducla, Eduard Vrdoljak, Joseph Gligorov, R. Deurloo, V. Easton, G. von Minckwitz, Norbert Marschner, J. Cortes Castan, Christoph C. Zielinski, Fabio Puglisi
Publikováno v:
Annals of Oncology. 27:vi533
Autor:
Ulrich Freudensprung, Eduard Vrdoljak, S. de Ducla, Cristian Villanueva, Eva Ciruelos, M. De Laurentiis, G. von Minckwitz, Joseph Gligorov, István Láng, Gilles Romieu, J. Cortes, Christoph C. Zielinski, Corinne Veyret, Norbert Marschner, Fabio Puglisi, Stefanie Srock
Publikováno v:
Annals of Oncology. 25:iv117
Aim: Combining BEV with 1st- or 2nd-line chemotherapy (CT) improves progression-free survival (PFS) in HER2-negative LR/mBC. The open-label randomised phase III TANIA trial evaluated further BEV in BEV-pretreated LR/mBC. Methods: Patients (pts) whose
Autor:
Joseph Gligorov, Paulo Cortes, S. de Ducla, José Bines, Stefanie Srock, Ulrich Freudensprung, Zefei Jiang, Giorgio Mustacchi, Dinesh Chandra Doval, Emilio Alba
Publikováno v:
Annals of Oncology. 25:iv116
Background: Until regulatory withdrawal of BEV–DOC in 2011, the combination was considered a valid first-line option for HER2-negative mBC based on results of a phase III trial [Miles, JCO 2010]. Progression-free survival (PFS) and response rate (R
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.